Immix Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Immix Biopharma, Inc. filed this Form 8-K on June 9, 2022, reporting matters submitted to stockholders at the June 8, 2022 annual meeting. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol IMMX.
Annual Meeting Results
A quorum of 10,248,485 shares was represented in person or by valid proxy.
| Proposal | Result | Key Vote |
|---|---|---|
| Election of seven directors | All nominees elected to serve until the next annual meeting or until their successors are elected and qualified | For votes ranged from 8,534,711 to 8,568,040; broker non-votes totaled 1,642,653 for each nominee |
| Ratification of KMJ Corbin & Company LLP | Approved as independent registered public accounting firm for fiscal year ending December 31, 2022 | 9,023,287 for; 1,213,599 against; 11,599 abstain |
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Material Changes, Guidance, and Risks
The filing reports governance and auditor-ratification matters only. It does not provide guidance, an operating outlook, management commentary on performance, new contingencies, or unusual financial items. No material change versus a prior comparable period is disclosed.
Important Facts to Verify
- Confirm the continued composition of the seven-member board following the annual meeting.
- Verify the scope and terms of KMJ Corbin & Company LLP’s audit engagement for the year ending December 31, 2022.
- Review the company’s periodic financial filings for cash runway, funding requirements, operating results, debt, and clinical-development risks, which are not addressed in this Form 8-K.